Downloadedfromhttps://academic.oup.com/jcem/article/105/8/2475/5821255byUNIVERSITYOFPATRAS-LIBRARY&INFORMATIONSERVICEuseron20September2020
2486Fleminget?alEvolvingEvidenceofDKAWithSGLT2i?UseJClinEndocrinolMetab,August2020,105(8):2475–2486
54.Tougaard?NH,Faber?J,Eldrup?E.Verylowcarbohydratedietand68.Andrews?TJ,Cox?RD,Parker?C,Kolb?J.Euglycemicdiabetic
SGLT-2-inhibitor:doublejeopardyinrelationtoketoacidosis.ketoacidosiswithelevatedacetoneinapatienttakingasodium-
BMJCaseRep.2019;12(4).glucosecotransporter-2(SGLT2)inhibitor.JEmergMed.
55.Burgio?A,Alletto?M,Amico?S,et?al.Euglycemicdiabeticketo-2017;52(2):223-226.
acidosisintype2diabetesmellitustreatedwithsodium-glucose69.Adachi?J,Inaba?Y,Maki?C.Euglycemicdiabeticketoacidosis
cotransporter2inhibitors.A?reportontwocases.ItalJMed.withpersistentdiuresistreatedwithcanagliflozin.InternMed.
2019;13(1):54.2017;56(2):187-190.
56.González?Sanchidrián?S,Gómez-Martino?Arroyo?JR,70.Benmoussa?JA,Clarke?M,Penmetsa?A,et?al.Euglycemicdiabetic
Labrador?Gómez?PJ.Diabeticketoacidosisassociatedtocanagliflozinketoacidosis:theclinicalconcernofSGLT2inhibitors.JClin
intype2diabetes.MedClin(Barc).2017;148(4):e19-e20.TranslEndocrinol.2016;2:17-19.
57.Kohler?S,Zeller?C,Iliev?H,Kaspers?S.SafetyandTolerabilityof71.Gammons?DT,Counselman?FL.Sodium-glucosecotransporter-2
EmpagliflozininPatientswithType2Diabetes:PooledAnalysisinduceddiabeticketoacidosiswithminimalhyperglycemia.Clin
ofPhaseI–IIIClinicalTrials.UnitedStates:SpringerScience+PractCasesEmergMed.2018;2(1):47-50.
BusinessMedia;2017:1707.72.Shoukat?S,Usmani?NA,Soetan?O,Qureshi?F.Euglycemicdiabeticketo-
58.Erondu?N,Desai?M,Ways?K,Meininger?G.DiabeticKetoacidosisacidosisaccompaniedbyseverehypophosphatemiaduringrecovery
andRelatedEventsintheCanagliflozinType2DiabetesClinicalinapatientwithtype2diabetesbeingtreatedwithcanagliflozin/
Program.UnitedStates:AmericanDiabetesAssociationInc;metformincombinationtherapy.ClinDiabetes.2017;35(4):249-251.
2015:1680.73.Turner?J,Begum?T,Smalligan?RD.Canagliflozin-induceddiabetic
59.Jabbour?S,Seufert?J,Scheen?A,Bailey?CJ,Karup?C,Langkilde?AM.ketoacidosis:casereportandreviewoftheliterature.JInvestig
Dapagliflozininpatientswithtype2diabetesmellitus:apooledMedHighImpactCaseRep.2016;4(3):2324709616663231.
analysisofsafetydatafromphaseIIb/IIIclinicaltrials.Diabetes74.Fralick?M,Schneeweiss?S,Patorno?E.Riskofdiabeticketo-
ObesMetab.2018;20(3):620-628.acidosisafterinitiationofanSGLT2inhibitor.NEnglJMed.
60.Fadini?GP,Bonora?BM,Avogaro?A.SGLT2inhibitorsanddia-2017;376(23):2300-2302.
beticketoacidosis:datafromtheFDAAdverseEventReporting75.Woo?V,Bell?A,Clement?M,et?al.CANadianCAnagliflozin
System.Diabetologia.2017;60(8):1385-1389.REgistry:effectivenessandsafetyofcanagliflozininthetreatment
61.SevereeuglycaemicketoacidosiswithSGLT2inhibitoruseintheoftype2diabetesmellitusinCanadianclinicalpractice.Diabetes
perioperativeperiod.AustralianDiabetesSociety;2018.https://ObesMetab.2019;21(3):691-699.
diabetessociety.com.au/documents/2018_ALERT-ADS_SGLT2i_76.Jensen?ML,Persson?F,Andersen?GS,et?al.Incidenceofketoacidosisin
PerioperativeKetoacidosis_v3__final2018_02_14.pdf.AccessedtheDanishtype2diabetespopulationbeforeandafterintroductionof
July12,2019.sodium-glucosecotransporter2inhibitors-anationwide,retrospective
62.EMAconfirmsrecommendationstominimiseketoacidosisriskcohortstudy,1995-2014.DiabetesCare.2017;40(5):e57-e58.
withSGLT2inhibitorsfordiabetes.EuropeanMedicinesAgency;77.Lucero?P,Chapela?S.Euglycemicdiabeticketoacidosisinthe
2016.https://www.ema.europa.eu/en/documents/referral/sglt2-ICU:3casereportsandreviewofliterature.CaseRepCritCare.
inhibitors-article-20-procedure-ema-confirms-recommendations-2018;2018:1747850.
minimise-ketoacidosis-risk-sglt2_en.pdf.AccessedJuly23,2019.78.Barski?L,Eshkoli?T,Brandstaetter?E,Jotkowitz?A.Euglycemic
63.HandelsmanY,HenryRR,BloomgardenZT,etal.Americandiabeticketoacidosis.EurJInternMed.2019;63:9-14.
AssociationofClinicalEndocrinologistsandAmericanCollege79.Danne?T,Garg?S,Peters?AL,et?al.Internationalconsensusonrisk
ofEndocrinologypositionstatementontheassociationofmanagementofdiabeticketoacidosisinpatientswithtype1dia-
SGLT-2inhibitorsanddiabeticketoacidosis.EndocrPract.betestreatedwithSodium-GlucoseCotransporter(SGLT)inhibi-
2016;22(6):753-762.tors.DiabetesCare.2019;42(6):1147-1154.
64.FDAAdverseEventsReportingSystem(FAERS)Public80.Meyer?EJ,Gabb?G,Jesudason?D.SGLT2inhibitor-associated
Dashboard.FederalDrugAdministration;2019.https://fis.euglycemicdiabeticketoacidosis:aSouthAustralianclinicalcase
fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/seriesandaustralianspontaneousadverseeventnotifications.
sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis.DiabetesCare.2018;41(4):e47-e49.
AccessedAugust25,2019.81.Tran?TTT,Pease?A,Wood?AJ,et?al.ReviewofEvidenceforAdult
65.Blau?JE,Tella?SH,Taylor?SI,Rother?KI.KetoacidosisassociatedDiabeticKetoacidosisManagementProtocols.FrontEndocrinol.
withSGLT2inhibitortreatment:analysisofFAERSdata.Diabetes2017;8:106.
MetabResRev.2017;33(8):e2924.doi:10.1002/dmrr.292482.Finfer?S,Liu?B,Chittock?DR,et?al.Hypoglycemiaand
66.Bardia?A,Wai?M,Fontes?ML.Sodium-glucosecotransporter-2in-riskofdeathincriticallyillpatients.NEnglJMed.
hibitors:anoverviewandperioperativeimplications.CurrOpin2012;367(12):1108-1118.
Anaesthesiol.2019;32(1):80-85.83.Patakfalvi?L,Brazeau?AS,Dasgupta?K.Physicianexperiences
67.Allison?R,Goldstein?D,Musso?MW.Challengesinthediagnosiswithsodium-glucosecotransporter(SGLT2)inhibitors,a
ofeuglycemicdiabeticketoacidosisina?patientwithmultiplenewclassofmedicationsintype2diabetes,andadverseef-
sclerosistakingasodium-glucosecotransporter2inhibitor.Jfects.PrimHealthCareResDev.2019;20:E50.doi:10.1017/
EmergMed.2019;57(1):e1-e3.S1463423618000476 |
|
